中国肿瘤生物治疗杂志2025，Vol.32Issue(1)：14-23,10.DOI:10.3872/j.issn.1007-385x.2025.01.003
小细胞肺癌免疫治疗:进展与挑战
Immunotherapy for small cell lung cancer:progresses and challenges
摘要
Abstract
Small cell lung cancer(SCLC)is the most aggressive type of lung cancer,accounting for approximately 13%to 15%of all lung cancer cases.Although SCLC patients are highly responsive to chemotherapy and radiotherapy at their initial treatment,they are prone to relapse,leading to a low survival rate.Since 2018,with the success of the IMpower133 and CASPIAN trials,SCLC has entered the era of immunotherapy.Chemotherapy combined with immune checkpoint inhibitors(ICIs)has become the standard first-line treatment for extensive-stage SCLC.Meanwhile,immunotherapy has also achieved preliminary success in limited-stage SCLC.Despite some progress in SCLC immunotherapy,the overall survival benefit remains limited.There is a lack of effective predictive biomarkers,and treatment options for relapsed/refractory SCLC are scarce,posing significant challenges to the future of immunotherapy in SCLC.In this article,the latest clinical research on SCLC immunotherapy,both domestically and internationally,is reviewed,different types of immunotherapeutic agents,biomarkers,and novel immunotherapy targets are analyzed,and the combination strategies and future prospects of SCLC immunotherapy are discussed.关键词
小细胞肺癌/免疫治疗/免疫检查点抑制剂/程序性死亡受体1/程序性死亡配体1/生物标志物Key words
small cell lung cancer(SCLC)/immunotherapy/immune checkpoint inhibitor(ICI)/programmed death 1(PD-1)/programmed death-ligand 1(PD-L1)/biomarker分类
临床医学引用本文复制引用
廖成功,张贺龙..小细胞肺癌免疫治疗:进展与挑战[J].中国肿瘤生物治疗杂志,2025,32(1):14-23,10.基金项目
国家自然科学基金(No.82372971) （No.82372971）
